Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Gene replacement therapy is an attractive approach for treatment of genetic disease, but may be complicated by the risk of a neutralizing immune response to the therapeutic gene product. There are examples of humoral and cellular immune responses against the transgene product as well as absence of such responses, depending on vector design and the underlying mutation in the dysfunctional gene. It has been unclear, however, whether transgene expression can induce tolerance to the therapeutic antigen. Here, we demonstrate induction of immune tolerance to a secreted human coagulation factor IX (hF.IX) antigen by adeno-associated viral gene transfer to the liver. Tolerized mice showed absence of anti-hF.IX and substantially reduced in vitro T cell responses after immunization with hF.IX in adjuvant. Tolerance induction was antigen specific, affected a broad range of Th cell subsets, and was favored by higher levels of transgene expression as determined by promoter strength, vector dose, and mouse strain. Hepatocyte-derived hF.IX expression induced regulatory CD4(+) T cells that can suppress anti-hF.IX formation after adoptive transfer. With a strain-dependent rate of success, tolerance to murine F.IX was induced in mice with a large F.IX gene deletion, supporting the relevance of these data for treatment of hemophilia B and other genetic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“mouse studies have shown liver-directed AAV gene therapy results in tolerogenic responses by the induction of Tregs,52, 53, 54, 55, 56, 57, 58, 59”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [53]
The cited source says what the claim attributes to it.
In the citing paper
“It has been shown in multiple preclinical (160, 168 -171) and clinical studies (34) that liver-targeted AAV delivery induced immune tolerance of transgene products.”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [34]
In the citing paper
“The immunogenic i.m. route was chosen for these experiments, as hepatic gene transfer typically results in tolerance induction to FIX (24, 38).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [24]
In the citing paper
“Expression of DTR under XCR1 promoter allowed specific depletion of XCR1+ DCs by administration of diphtheria toxin (DT) whereas expression of fluorescent protein allowed their easy detection and tracking.”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [24]
In the citing paper
“Fortunately, the immune response is not always against AAV-mediated gene transfer, evidenced by induction of regulatory T cells (Tregs) that suppress immune response and facilitate sustained transgene expression (34, 35).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [34]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic Cell Subsets and Lineages, and Their Functions in Innate and Adaptive Immunity
Liu, Y.-J. (2001) · Cell · doi:10.1016/s0092-8674(01)00456-1 · Cited by 1,004
Self-citationInduction and mechanism of action of transforming growth factor‐β‐secreting Th3 regulatory cells
Weiner, H. L. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820117.x · Cited by 846 · cited 7×
“We do not know at this point whether TGF-β in hepatic tolerance is derived from regulatory Th3 cells or a different cell type.”
BackgroundInfluentialRoncarolo, M. G., Bacchetta, R., Bordignon, C., Narula, S., & Levings, M. K. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820105.x · Cited by 814 · cited 6×
“We do not know at this point whether TGF-β in hepatic tolerance is derived from regulatory Th3 cells or a different cell type.”
BackgroundInfluentialLimmer, A., Ohl, J., Kurts, C., Ljunggren, H.-G., Reiss, Y., Groettrup, M., Momburg, F., Arnold, B., & Knolle, P. A. (2000) · Nature Medicine · doi:10.1038/82161 · Cited by 758 · cited 1×
“Liver transplants are often not rejected even across MHC barriers, and LSECs have been shown to represent specialized APCs that can induce T cell tolerance (40, 42).”
BackgroundLocal control of the immune response in the liver
Knolle, P. A., & Gerken, G. (2000) · Immunological Reviews · doi:10.1034/j.1600-0528.2002.017408.x · Cited by 603 · cited 3×
“) promotes tolerance rather than immunity to the transgene product (40).”
BackgroundSnyder, R. O., Miao, C. H., Patijn, G. A., Spratt, S. K., Danos, O., Nagy, D., Gown, A. M., Winther, B., Meuse, L., Cohen, L. K., et al. (1997) · Nature Genetics · doi:10.1038/ng0797-270 · Cited by 579
Herzog, R. W., Yang, E. Y., Couto, L. B., Hagstrom, J. N., Elwell, D., Fields, P. A., Burton, M., Bellinger, D. A., Read, M. S., Brinkhous, K. M., et al. (1999) · Nature Medicine · doi:10.1038/4743 · Cited by 554 · cited 3×
“IX vectors to adults with severe hemophilia B were initiated (4, 5, 8, 9).”
BackgroundSelf-citationAdeno-associated virus vectors can be efficiently produced without helper virus
Matsushita, T., Elliger, S., Elliger, C., Podsakoff, G., Villarreal, L., Kurtzman, G., Iwaki, Y., & Colosi, P. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300680 · Cited by 500 · cited 1×
“AAV vector (serotype 2) was produced by triple transfection of HEK-293 cells, purified by CsCl-gradient centrifugation, and quantitated by dot blot hybridization as described (23).”
MethodNakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., & Kay, M. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6969-6976.2001 · Cited by 478 · cited 1×
“IX as designed by Kay and colleagues (22).”
MethodJooss, K., Yang, Y., Fisher, K. J., & Wilson, J. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.4212-4223.1998 · Cited by 470 · cited 5×
“Even with a ubiquitous promoter, hepatocytes are the major site of F.IX synthesis following portal infusion of AAV vector, which has a strong tropism for liver and does not appear to transduce other cell types within the liver or APCs (24, 43, 44).”
BackgroundInfluential
Research works printed but not linked: 2
- Manno, C.S., et al. 2003. A phase I safety study in patients with severe hemophilia B using adeno-associated viral (AAV) vector to deliver the gene for human factor IX to skeletal muscle. Blood . In press.
- Nakai, H., et al. 2000. A proposed rAAV-liver directed clinical trial for hemophilia B. Blood. 96 (Suppl.):798a-799a.
Cited by
Items 401–471 of 471
Repurposing the skin to heal the body: Tissue Nanotransfection (TNT) as a therapeutic platform
Salazar‐Puerta, A. I., Stanford, K., Higuita‐Castro, N., & Gallego‐Perez, D. (2026) · Med-X · doi:10.1007/s44258-026-00084-8 · Cited by 2
“One mitigating factor is that in situ production occurs under constant immune surveillance, which may improve tolerability [26–29].”
Hemophilia gene therapy: it's a matter of expression
Lillicrap, D. (2003) · Blood · doi:10.1182/blood-2003-10-3531 · Cited by 1
The Need for Gene Therapy for the Effective Treatment of Hemophilia
Wynn, T., Slayton, W. B., & Herzog, R. W. (2013) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.s1-016 · Cited by 1
“In addition, factor IX deficient mice largely have remained free of inhibitors when gene transfer occurred within the liver [9].”
BackgroundSelf-citationLiu, A. B., Tai, K. F., & Lin, S. Z. (2005) · Tzu Chi Medical Journal · doi:10.6440/tzucmj.200502.0075 · Cited by 1
“This concept has been used to attenuate host immune responses and prolong expression of the transgene [17,18].”
MethodMartinet, J., Bourdenet, G., Meliani, A., Jean, L., Adriouch, S., Cohen, J. L., Mingozzi, F., & Boyer, O. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00360 · Cited by 1
“Only few tolerizing strategies have been investigated to tackle this issue, mostly by targeting FIX expression to the liver (5, 13) or detargeting transgene expression from antigen-presenting cells (11).”
Self-citationAsp, P., Guha, C., Chowdhury, N. R., & Chowdhury, J. R. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch73 · Cited by 1
Asghar, A., Asjad, Z., Tahir, H., Maheen, Z., & Hanif, S. (2021) · Pakistan Journal of Intensive Care Medicine · doi:10.54112/pjicm.v2021i1.6 · Cited by 1
Immunogenicity of AAV Gene Therapy Products
Jawa, V., & Wu, B. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch5 · Cited by 1
Detection of Humoral Response to Transgene Protein and Gene Editing Reagents
Buchlis, G., & Gorovits, B. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch12 · Cited by 1
Liao, K. A., Lim, J., Choi, S. J., Yi, H., & Sun, B. (2025) · Advances in Cell and Gene Therapy · doi:10.1155/acg2/4639392 · Cited by 2
“Liver-directed AAV gene therapy using a liver-speci fi c promoter (LSP) is a proven approach to induce immune tolerance to therapeutic transgene products [25, 26].”
The State of the Art and Future of Gene Medicines
Jacobs, F., Gordts, S. C., & Geest, B. D. (2013) · Wiley eBooks · doi:10.1002/9780470571224.pse515 · Cited by 1
High, K. A. (1998) · Wiley eBooks · doi:10.1002/0471223956.ch15 · Cited by 1
Self-citationLiver gene transfer keeps immune system in check
VandenDriessche, T. (2004) · Blood · doi:10.1182/blood-2004-05-1977 · Cited by 1
Domenico, C. D., Napoli, D. D., Reyero, E. G. Y., Lombardo, A., Naldini, L., & Natale, P. D. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.ft-253 · Cited by 1
Tratamiento génico: futuro o fracaso
Park, F., & Gow, K. W. (2006) · Clínicas pediátricas de Norteamérica
Induction of Immunological Tolerance to Transgene Products
Sack, B. K., Markusic, D. M., & Herzog, R. W. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5480-9_15
Self-citationGene Therapy of Lysosomal Storage Disorders by Lentiviral Vectors
Biffi, A., & Naldini, L. (2007) · Springer eBooks · doi:10.1007/978-0-387-70909-3_10
Mah, C. S. (2005) · Laboratory techniques in biochemistry and molecular biology · doi:10.1016/s0075-7535(05)31003-5
Immunity and tolerance induction in gene therapy
Davoust, J. M., Bertho, N., Masurier, C., & Gross, D. (2005) · Wiley eBooks · doi:10.1002/047001153x.g107305
Translational Challenges for Hepatocyte-Directed Gene Transfer
Stephanie, C., Van, E., Jacobs, F., & De, B. (2011) · InTech eBooks · doi:10.5772/22930
Gene Therapy Trials in Hemophilia A and B
High, K. A. (2014) · Wiley eBooks · doi:10.1002/9781118398258.ch41
Self-citationInducing Tregs with hepatic gene therapy
Lillicrap, D. (2007) · Blood · doi:10.1182/blood-2007-05-087718
Protein transduction for tolerance induction
Rogers, G. L., & Herzog, R. W. (2011) · Clinical Immunology · doi:10.1016/j.clim.2011.05.001
Self-citationLentiviral vector for hemophilia gene therapy
Herzog, R. W. (2004) · Blood · doi:10.1182/blood-2004-03-0820
Self-citationUse of a Bacterially Expressed Human Factor IX Light Chain to Develop Polyclonal Antibody Anti-hFIX
Safari, S., Zomorodipour, A., Amirmozafari, N., & Choopari, M. D. (2009) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-008-8506-7
Immune modulation in gene therapy studies
Aerts‐Kaya, F., Kaptein, L. C. M., & Wagemaker, G. (2010) · RePub (Erasmus University Rotterdam)
Adipose-tissue derived hepatic stem cells for gene therapy: Fat goes to liver’s rescue?
Ferry, N. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.11.009 · Cited by 1
Hengge, U. R., Bardenheuer, W., Doroudi, R., & Mirmohammadsadegh, A. (2005) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/s0151-9638(05)79230-9
Ponder, K. P. (2005) · Wiley eBooks · doi:10.1002/9780470987124.ch38
Treating Hemophilia by Gene Therapy
Porada, C. D., Ignacio, G., Atala, A., & Almeida-Porada, G. D. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800548-4.00012-7
Ishiguro, A. (2011) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.34.476
Interferon limits lentiviral vectors in the liver
Herzog, R. W. (2007) · Blood · doi:10.1182/blood-2007-01-067207
Self-citationIntracellular fate of AAV particles in human Dendritic Cell and impact on Gene Transfer
Rossi, A. (2016) · theses.fr (ABES) · doi:10.70675/4518d4eazdbd8z4f46z96e2zf87942913c70
Reeves, P. (2016) · The University of Queensland · doi:10.14264/uql.2016.980
Wilson, J. M., & Wivel, N. A. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-369420-1.00053-6
結核菌の縦列反復配列多型(VNTR)解析に基づく分子疫学とその展望 : 大阪市の例
和田, 崇., & 長谷, 篤. (2010) · 結核
Mingozzi, F., & Junge, N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-63671-1.00033-1
Self-citationSafety Aspects of Genome Editing
Chandode, R. K., & Nitsch, R. (2022) · Wiley eBooks · doi:10.1002/9781119671404.ch19
Fehlings, M. G. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734958350.793573257
Faculty Opinions recommendation of Efficient In Vivo Liver-Directed Gene Editing Using CRISPR/Cas9.
Conboy, I. M. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732930845.793553932
Enhancers for Selective Targeting
Lin, J. D., & Dimidschstein, J. (2023) · Neuromethods · doi:10.1007/978-1-0716-2918-5_9
LSpECifying transgene expression
Annoni, A., & Cantore, A. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102144
Schiller, L., Ko, C., Kosinska, A. D., Grimm, D., & Protzer, U. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-4027-2_18
Missense and nonsense mutations and inhibitor development in patients with hemophilia A and B
Karimi, F., Saki, N., Khademi, R., Kaydani, G. A., & Keikhaei, B. (2025) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-025-03171-6
“Herzog et al. demonstrated that liver-directed gene therapy can both induce tolerance and clear high-titer inhibitors in mice, with effects dependent on Tregs and B cell modula - tion [80 , 81 ].”
Deng, M., Zhou, H., He, S., Qiu, H., Wang, Y., Zhao, A. Y., Mu, Y., Li, F., & Zhao, A. Z. (2023) · Figshare · doi:10.6084/m9.figshare.24091765
Self-citationVicidomini, A. (2024) · Open Research Online (The Open University) · doi:10.21954/ou.ro.00097257
Preclinical Safety and Tolerability of an AAV Vector Expressing TLR9 in Mice and HamstersPreprint
Wootton, S. K., Yang, C., Santos, I., & Thompson, B. (2026) · Research Square · doi:10.21203/rs.3.rs-8545024/v1
Balancing Promise and Peril: Hemophilia Gene Therapy Insights
Akula, S., Borroni, E., Cottonaro, A., Follenzi, A., & Merlin, S. (2026) · IUBMB Life · doi:10.1002/iub.70087
“Initial studies on tolerance induction via gene therapy were performed in a mouse model of hemophilia B, demonstrating that gene therapy has the potential to induce tolerance and prevent the formation of FIX inhibitors [76, 77].”
Les vecteurs AAV recombinants : un nouvel outil de vaccination contre les Hénipavirus
Ploquin, A. (2012) · theses.fr (ABES) · doi:10.70675/a11367cfzedd0z46bbz8125zcec139d25083
Carpentier, M. (2013) · theses.fr (ABES) · doi:10.70675/fa69ca30zf46az45f1z9638z003bd41555e4
Propriétés de reconnaissance antigénique des lymphocytes T régulateurs CD4+ FOXP3+
Lalfer, M. (2015) · theses.fr (ABES) · doi:10.70675/64648159z6aa9z4b18z8768z8e24ccef8373
Alteration of alternative splicing in the pathogenesis of liver disease
Wang, H. (2017) · theses.fr (ABES) · doi:10.70675/bbd0da03z44bcz4adczaedazc17212ba6ebe
Sargent, D. (2018) · theses.fr (ABES) · doi:10.70675/2cd4ead6z0cd7z476dz8376z54bb3bd9a0ea
Bartolo, L. (2018) · theses.fr (ABES) · doi:10.70675/b32b9711za15dz4740z8481z0ba7dd36e8ee
Développement d'un traitement de thérapie génique pour la glycogénose de type III
Vidal, P. (2018) · theses.fr (ABES) · doi:10.70675/5e174471z66d8z44dbza2edz3adc480b1f41
Verdera, H. C. (2019) · theses.fr (ABES) · doi:10.70675/3d2d8524z211ez4408zbdfbz56c065f452a1
Journou, M. (2021) · theses.fr (ABES) · doi:10.70675/9a618ac2za0a4z4e90zbdb3ze14482ffa655
Etude des réponses T CD8+ après transfert de gène par rAAV ciblant le muscle
Jeanpierre, L. (2024) · theses.fr (ABES) · doi:10.70675/430aceacz50d2z426bz907dz876c55d1e935
Jeanpierre, L., Pecquet, C., Saliba, H., Finard, P., Terry, S., Tavella, G., Guesmia, I., Boutin, S., Bertin, B., Benkhelifa‐Ziyyat, S., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.202541
“…regulation in reducing immune responses has been demonstrated for muscle targeting (15–17, 21– 24) and liver-directed liver-directed gene transfer ( 19, 20, 37, Using a single MHC class I epitope allowed us to assess CD8 + responses independently of CD4 + help, antibodies, or regulatory T cells.”
Li, Y., Nandy, P., Jordie, E. B., Knab, T. D., Peppel, K., Kirouac, D. C., Wilkins, A. K., & Nuthalapati, S. (2026) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70286 · Cited by 1
Hu, B., Gutty, V. S. R., Herzog, R. W., & Duan, D. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1930231
“Thus, antigen load influences the kinetics of the immune response and the balance between immunity and tolerance (79, 80).”
Self-citationHepatotoxicity in Adeno-Associated Virus Gene Therapy: Clinical Challenges and Strategic Solutions
Asai, A., Aqul, A. A., Banc‐Husu, A. M., Diamond, T., Elisofon, S. A., Freeman, A. J., Loomes, K. M., Mohammad, S., Sundaram, S. S., & Chapin, C. A. (2026) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2026.115317
Clinical immunogenicity in rAAV gene therapy: Insights and implications
Gulve, N., Bego, M. G., Gandhi, H., Khan, Z., Tong, O., Katebifar, S., & Rajadhyaksha, M. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201848 · Cited by 1
“17 Beyond these determinants, the qualitative features of the immune response to rAAV can be understood within the classical framework of a protective immune response against an infectious agent, which generally involves three signals: an innate immune danger signal, an antigen-specific signal, and…”
Saxena, H., Romano, G., Domenis, R., Biasizzo, J., Ferro, M., Ferino, D., Vicidomini, A., Colliva, A., Iaconcig, A., Bortolussi, G., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201864
Metadata
- Authors
- Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J. H., Wang, Y., Arruda, V. R., High, K. A., & Herzog, R. W.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Corresponding author
- Herzog, Roland W.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2003-05-01
- Volume
- 111
- Issue
- 9
- Pages
- 1347-1356
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC154443
- OpenAlex
- W4250446838
- Cited by
- 466
- References
- 44
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 19 · 2023: 11 · 2022: 17 · 2021: 16 · 2020: 19 · 2019: 21 · 2018: 24 · 2017: 29 · 2016: 13 · 2015: 18 · 2014: 21 · 2013: 17 · 2012: 23
- FWCI
- 13.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Hemophilia Foundation
- Hemophilia of Georgia
- National Institutes of Health (5r01hl061921-02)
- National Heart, Lung, and Blood Institute (R01 HL61921)
- National Institute of Allergy and Infectious Diseases (R01 AI/HL 51390-01)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immune tolerance, coagulation factor IX, AAV gene delivery, hepatic gene transfer, gene replacement therapy, hemophilia B, regulatory T cells, T cell tolerance, transgene expression, secreted antigens, humoral immune response
- MeSH terms
- Dependovirus, Animals, Antibodies, Hemophilia B, Factor IX, Humans, Immune Tolerance, Liver, Mice, Inbred Strains, Promoter Regions, Genetic, Receptors, Antigen, T-Cell, T-Lymphocytes, Genetic Therapy, Interleukin-4, Gene Transfer Techniques, Mice, Knockout, fas Receptor, Adoptive Transfer, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.